According to Iris's announcement, the first-line treatment indication for EGFR 20 exon insertion mutation non-small cell lung cancer of the new class 1 drug vometinib mesylate developed independently by the company was added to the 2026 edition of the national medical insurance catalogue. The medical insurance classification is category B, and the agreement is valid from January 1, 2027 to December 31, 2027. The original first-line and second-line treatment indications of vometinib continued to be effective during the original agreement period. This matter helps improve drug accessibility and expand the beneficiary patient base. There is uncertainty about product sales being affected by factors such as market competition.

Zhitongcaijing · 2d ago
According to Iris's announcement, the first-line treatment indication for EGFR 20 exon insertion mutation non-small cell lung cancer of the new class 1 drug vometinib mesylate developed independently by the company was added to the 2026 edition of the national medical insurance catalogue. The medical insurance classification is category B, and the agreement is valid from January 1, 2027 to December 31, 2027. The original first-line and second-line treatment indications of vometinib continued to be effective during the original agreement period. This matter helps improve drug accessibility and expand the beneficiary patient base. There is uncertainty about product sales being affected by factors such as market competition.